HB 1045 modifies Maryland’s Prescription Drug Monitoring Program (PDMP) by adding a restriction on sharing prescription data with federal law enforcement. Specifically, it amends Section 21-2A-06(b)(4) of the Maryland Annotated Code to prohibit disclosure to federal agencies unless the data does not involve "sensitive health services" designated by the new Protected Health Care Commission. This Commission, established under Section 4-310, will identify health services (like reproductive care) where data sharing could risk patient safety or privacy. The bill directly affects healthcare providers and patients whose data might be monitored, particularly for sensitive health services, by requiring a review before federal disclosure.
HB 1440 prevents Medicaid plans and certain health insurers from requiring extra approval steps (like prior authorization) or limiting coverage for prescription drugs reviewed by Maryland's Prescription Drug Affordability Board (PDAB). It specifically applies when the PDAB hasn't determined a drug causes cost concerns, has made a policy recommendation, or set a payment limit for the drug. This directly affects patients using these medications by reducing barriers to accessing covered drugs. The bill updates Maryland's health insurance and Medicaid laws to enforce these restrictions on managed care organizations and insurers.
SB 839 requires Maryland's Department of Health to conduct a survey of pharmacy dispensing costs in the state every three years starting in 2026. Within six months after each survey, the Department must establish a fee charged to pharmacies for dispensing drugs under the state's Medical Assistance Program (Medicaid). This fee will be based directly on the survey results, aiming to reflect actual dispensing costs. The bill applies specifically to pharmacies participating in Maryland's Medicaid program and takes effect October 1, 2026.
SB 837 prohibits Maryland insurance companies, health plans, and managed care organizations from requiring prior authorization, step therapy, or coverage restrictions for prescription drugs reviewed by the Prescription Drug Affordability Board (PDAB). It specifically blocks these requirements if the PDAB has not determined the drug causes an affordability challenge, has made a policy recommendation about it, or has set an upper payment limit. The bill directly affects patients needing covered medications and insurers that must comply with these new coverage rules. It aims to streamline access to PDAB-reviewed drugs by removing common insurance barriers without altering the drugs' clinical use.
HB 1377 establishes a 18-month pilot program to redirect unused, unopened prescription drugs to a state repository program. It requires participating pharmacies (repositories) to collect eligible medications during National Prescription Drug Take Back Days, package them properly, and transfer them to designated drop-off sites for distribution to eligible patients - while sending controlled substances directly to the DEA. The program aims to expand medication access for underserved communities, reduce pharmaceutical waste, and ensure drug safety through collaboration between Maryland’s Secretary of Health and the federal DEA. The pilot runs from July 2026 through December 2027, with mandatory reporting on collected medications by October 1, 2027.
HB 1075 expands eligibility for Maryland's Graduate and Professional Scholarship Program to include students at the University of Maryland Eastern Shore (UMES) enrolled in four specific degree programs: Master of Medical Science in Physician Assistant Studies, Doctor of Pharmacy, Doctor of Physical Therapy, and Doctor of Veterinary Medicine. This change directly affects UMES students in these fields who previously could not qualify for the scholarship. The bill amends the existing law by adding UMES to the list of eligible institutions under the program's criteria, which requires applicants to be Maryland residents attending approved institutions in designated health-related fields. The policy change takes effect July 1, 2026, allowing UMES students to access this financial aid for the first time.
SB 778 creates a new "clinical research pharmacy permit" required for pharmacies conducting clinical trials in Maryland. It allows healthcare providers to own such pharmacies under specific conditions, including requiring a licensed pharmacist to be on-site at all times and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations from being classified as "practice of medicine," removing a licensing barrier for these activities. This directly affects pharmacies seeking to operate clinical trials, healthcare providers considering ownership, and the State Board of Pharmacy (as the permit issuer).
SB 562 allows pharmacists in Maryland to treat opioid use disorders using medication therapy under specific conditions. It repeals a requirement that prescribers (like doctors) must submit agreements to their health board and instead authorizes pharmacists to enter into prescriber-pharmacist agreements if they meet qualifications such as holding a Doctor of Pharmacy degree, completing required training, and registering with federal agencies. The law mandates that any treatment protocol requires pharmacists to check the Prescription Drug Monitoring Program before starting or changing medication. This change aims to expand access to medication-based treatment for opioid use disorders by enabling pharmacists to provide care in pharmacy settings.
HB 1384 requires Maryland’s Department of Health to select and contract with a single State Pharmacy Benefits Manager (SPBM) by July 1, 2028. This SPBM will administer pharmacy benefits for all Medicaid recipients, including those enrolled in managed care plans, which must contract with and use the SPBM for all pharmacy services after that date. The bill prohibits "spread pricing" (where managers profit from price differences between pharmacies and the program) and mandates transparent pricing for drug costs, rebates, and fees. It directly affects Medicaid beneficiaries, managed care organizations, and pharmacies by centralizing pharmacy benefit management under state oversight.
HB 1385 requires health insurers and pharmacy benefit managers using artificial intelligence (AI) for medical treatment reviews (utilization review) to include licensed healthcare professionals in key evaluations. Specifically, it mandates that AI decisions must be reviewed by a licensed professional who can question, modify, or override AI determinations based on a patient’s full medical history and individual circumstances. The bill also requires quarterly reviews of AI performance using human assessments of real-world health outcomes to improve accuracy and safety. These provisions apply to all AI tools used in utilization review processes within Maryland’s health insurance system, effective October 1, 2026.
